GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIKLY) » Definitions » EV-to-EBIT

Grifols (Grifols) EV-to-EBIT

: 25.76 (As of Today)
View and export this data going back to 2008. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Grifols's Enterprise Value is $19,463 Mil. Grifols's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $755 Mil. Therefore, Grifols's EV-to-EBIT for today is 25.76.

The historical rank and industry rank for Grifols's EV-to-EBIT or its related term are showing as below:

GIKLY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.79   Med: 20.95   Max: 37.68
Current: 25.76

During the past 13 years, the highest EV-to-EBIT of Grifols was 37.68. The lowest was 7.79. And the median was 20.95.

GIKLY's EV-to-EBIT is ranked worse than
62.13% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.995 vs GIKLY: 25.76

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Grifols's Enterprise Value for the quarter that ended in Sep. 2023 was $22,450 Mil. Grifols's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $755 Mil. Grifols's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 3.37%.


Grifols EV-to-EBIT Historical Data

The historical data trend for Grifols's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.67 22.04 34.04 25.98 31.40

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.93 25.98 37.64 35.55 -

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Grifols's EV-to-EBIT falls into.



Grifols EV-to-EBIT Calculation

Grifols's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=19462.814/755.472
=25.76

Grifols's current Enterprise Value is $19,463 Mil.
Grifols's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $755 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols  (OTCPK:GIKLY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Grifols's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=755.472/22450.127
=3.37 %

Grifols's Enterprise Value for the quarter that ended in Sep. 2023 was $22,450 Mil.
Grifols's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $755 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Grifols's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols (Grifols) Business Description

Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.

Grifols (Grifols) Headlines

From GuruFocus

David Herro Comments on Grifols

By Sydnee Gatewood 04-14-2022